Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
Article CAS PubMed PubMed Central Google Scholar
Patel AB, O’Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin N Am. 2017;31:589–612.
Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.
Article CAS PubMed PubMed Central Google Scholar
Akard LP, Albitar M, Hill CE, Pinilla-Ibarz J. The “hit hard and hit early” approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer Network clinical practice guidelines for routine practice. Clin Adv Hematol Oncol. 2013;11:421–32.
Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15:323–34.
Article PubMed PubMed Central Google Scholar
Bosi GR, Fogliatto LM, Costa TEV, Grokoski KC, Pereira MP, Bugs N, et al. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials? Hematol Transfus Cell Ther. 2019;41:222–8.
Article PubMed PubMed Central Google Scholar
Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin N Am. 2011;25:981–95.
Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510–6.
Article CAS PubMed PubMed Central Google Scholar
Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38:10–20.
Article CAS PubMed Google Scholar
Dhillon S. Olverembatinib: first approval. Drugs. 2022;82:469–75.
Article CAS PubMed Google Scholar
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–80.
Article CAS PubMed Google Scholar
Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.
Article CAS PubMed Google Scholar
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404.
Article CAS PubMed PubMed Central Google Scholar
Deininger MW, Apperley JF, Arthur CK, Chuah C, Hochhaus A, De Lavallade H, et al. Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) By baseline BCR-ABL1 level and baseline mutation status in the OPTIC Trial. Blood. 2021;138:307.
Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, et al. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018;59:1312–22.
Article CAS PubMed Google Scholar
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042–50.
Article CAS PubMed PubMed Central Google Scholar
Molica M, Scalzulli E, Colafigli G, Foa R, Breccia M. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol. 2019;10:2040620719826444.
Article CAS PubMed PubMed Central Google Scholar
Iclusig (Ponatinib) [package insert]. Cambridge MTPCL.
Jabbour E, Kantarjian H, O’Brien S, Shan J, Quintas-Cardama A, Faderl S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541–6.
Article CAS PubMed PubMed Central Google Scholar
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29:1634–42.
Article CAS PubMed Google Scholar
Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024;38:475–81.
Article CAS PubMed PubMed Central Google Scholar
Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120–35.
Article CAS PubMed Google Scholar
Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7.
Article CAS PubMed Google Scholar
Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031–41.
Article CAS PubMed PubMed Central Google Scholar
Mauro MJ, Hughes TP, Kim D-W, Réa D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-Year phase 1 safety and efficacy results. Leukemia. 2023;37:1048–59.
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–26.
Article CAS PubMed PubMed Central Google Scholar
Novartis Pharmaceuticals Corporation. NDA/BLA Multi-disciplinary Review and Evaluation SCEMBLIX (asciminib). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000MultidisciplineR.pdf. Accessed 29 Apr 2024.
Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB. Exposure-efficacy analysis of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther. 2022;112:1040–50.
Scemblix (asciminib) [package insert]. East Hanover, NJ; Novartis Pharmaceutical Corporation. 2023.
Hughes TP, Cortes JE, Réa D, Mauro MJ, Hochhaus A, Kim D-W, et al. Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial. Presented at: EHA2022 Congress; June 9-17, 2022; Vienna, Austria, and Online. Poster P704.
Scemblix (asciminib) [prescribing information]. Macquarie Park N, Australia; Novartis Pharmaceuticals Australia Pty Limited; 2022.
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.
Article CAS PubMed PubMed Central Google Scholar
Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823–31.
Article CAS PubMed Google Scholar
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.
Article CAS PubMed Google Scholar
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.
Article CAS PubMed Google Scholar
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.
Article CAS PubMed PubMed Central Google Scholar
Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500.
Article CAS PubMed PubMed Central Google Scholar
Cortes J, Quintas-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011;117:1113–22.
Article CAS PubMed Google Scholar
Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415–23.
Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O’Brien S, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88:1024–9.
留言 (0)